[{"address1": "4 Kingsbury Avenue", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 607 0800", "fax": "617 607 0530", "website": "https://www.enanta.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 131, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay R. Luly Ph.D.", "age": 68, "title": "President, CEO & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1231428, "exercisedValue": 0, "unexercisedValue": 67815}, {"maxAge": 1, "name": "Mr. Paul J. Mellett Jr.", "age": 69, "title": "Chief Financial & Administrative Officer", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 671700, "exercisedValue": 0, "unexercisedValue": 21320}, {"maxAge": 1, "name": "Dr. Yat Sun Or Ph.D.", "age": 72, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 740108, "exercisedValue": 0, "unexercisedValue": 22091}, {"maxAge": 1, "name": "Mr. Matthew P. Kowalsky J.D.", "age": 51, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 575652, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott T. Rottinghaus M.D.", "age": 50, "title": "Chief Medical Office", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 776138, "exercisedValue": 43483, "unexercisedValue": 14728}, {"maxAge": 1, "name": "Ms. Jennifer  Viera", "title": "Executive Director of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathaniel S. Gardiner J.D.", "age": 70, "title": "Consultant", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 672675, "exercisedValue": 49136, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tara Lynn Kieffer Ph.D.", "age": 46, "title": "Chief Product Strategy Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 496852, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan  Luu", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 622856, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 4, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 5.06, "open": 5.08, "dayLow": 4.9604, "dayHigh": 5.34, "regularMarketPreviousClose": 5.06, "regularMarketOpen": 5.08, "regularMarketDayLow": 4.9604, "regularMarketDayHigh": 5.34, "payoutRatio": 0.0, "beta": 0.817, "forwardPE": -1.099585, "volume": 35155, "regularMarketVolume": 35155, "averageVolume": 328824, "averageVolume10days": 159470, "averageDailyVolume10Day": 159470, "bid": 3.77, "ask": 6.41, "bidSize": 2, "askSize": 2, "marketCap": 113062256, "fiftyTwoWeekLow": 4.09, "fiftyTwoWeekHigh": 17.235, "priceToSalesTrailing12Months": 1.697861, "fiftyDayAverage": 5.9378, "twoHundredDayAverage": 8.762425, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 112541672, "profitMargins": -1.5757099, "floatShares": 14292378, "sharesOutstanding": 21332500, "sharesShort": 2803726, "sharesShortPriorMonth": 2632482, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.1314, "heldPercentInsiders": 0.06579, "heldPercentInstitutions": 0.95726997, "shortRatio": 10.76, "shortPercentOfFloat": 0.1396, "impliedSharesOutstanding": 21332500, "bookValue": 5.241, "priceToBook": 1.0112574, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -104928000, "trailingEps": -4.95, "forwardEps": -4.82, "enterpriseToRevenue": 1.69, "enterpriseToEbitda": -1.044, "52WeekChange": -0.608662, "SandP52WeekChange": 0.08001411, "quoteType": "EQUITY", "currentPrice": 5.3, "targetHighPrice": 21.0, "targetLowPrice": 5.0, "targetMeanPrice": 15.14286, "targetMedianPrice": 18.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 216691008, "totalCashPerShare": 10.158, "ebitda": -107765000, "totalDebt": 221290000, "quickRatio": 5.237, "currentRatio": 5.467, "totalRevenue": 66591000, "debtToEquity": 197.905, "revenuePerShare": 3.142, "returnOnAssets": -0.17749001, "returnOnEquity": -0.691, "grossProfits": 66591000, "freeCashflow": -77771624, "operatingCashflow": -70577000, "revenueGrowth": -0.058, "grossMargins": 1.0, "ebitdaMargins": -1.61831, "operatingMargins": -1.38823, "financialCurrency": "USD", "symbol": "ENTA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NMS", "messageBoardId": "finmb_345286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Enanta Pharmaceuticals, Inc.", "longName": "Enanta Pharmaceuticals, Inc.", "regularMarketPrice": 5.3, "marketState": "REGULAR", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1363872600000, "regularMarketChange": 0.24000025, "regularMarketDayRange": "4.9604 - 5.34", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 328824, "fiftyTwoWeekLowChange": 1.21, "fiftyTwoWeekLowChangePercent": 0.2958435, "fiftyTwoWeekRange": "4.09 - 17.235", "fiftyTwoWeekHighChange": -11.935, "fiftyTwoWeekHighChangePercent": -0.6924862, "fiftyTwoWeekChangePercent": -60.8662, "regularMarketChangePercent": 4.743088, "corporateActions": [], "regularMarketTime": 1746724372, "earningsTimestamp": 1739221260, "earningsTimestampStart": 1754305140, "earningsTimestampEnd": 1754654400, "earningsCallTimestampStart": 1715027400, "earningsCallTimestampEnd": 1715027400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -4.95, "epsForward": -4.82, "epsCurrentYear": -4.42333, "priceEpsCurrentYear": -1.1981924, "fiftyDayAverageChange": -0.63779974, "fiftyDayAverageChangePercent": -0.10741348, "twoHundredDayAverageChange": -3.4624252, "twoHundredDayAverageChangePercent": -0.3951446, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "displayName": "Enanta Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-05-08"}]